PMID- 18768576
OWN - NLM
STAT- MEDLINE
DCOM- 20090508
LR  - 20181201
IS  - 1399-3003 (Electronic)
IS  - 0903-1936 (Linking)
VI  - 32
IP  - 6
DP  - 2008 Dec
TI  - The responsiveness and validity of the CAMPHOR Utility Index.
PG  - 1513-9
LID - 10.1183/09031936.00069708 [doi]
AB  - The aim of the present study was to validate and determine the minimal important 
      difference (MID) and responsiveness of the Cambridge Pulmonary Hypertension 
      Outcome Review (CAMPHOR) Utility Index, a new tool enabling cost utility 
      analyses. CAMPHOR, 6-min walking test (6MWT) and New York Heart Association 
      (NYHA) data for 869 pulmonary hypertension patients (545 (63%) female; mean+/-SD 
      age 56.6+/-15.4 yrs) from three centres were analysed. Utility was correlated 
      with 6MWT data and calculated by NYHA class to assess validity. Effect sizes were 
      calculated for those with two CAMPHOR assessments. Distribution and anchor-based 
      MIDs were calculated. Analyses were carried out in patients receiving bosentan in 
      order to determine whether or not those remaining in NYHA class III following 
      treatment improved. The Utility Index distinguished between adjacent NYHA classes 
      and correlated with 6MWT results. CAMPHOR subscales and utility were as 
      responsive as the 6MWT (effect sizes ranged 0.31-0.69 for the CAMPHOR and 
      0.16-0.34 for the 6MWT). The within-group MID for the Utility Index was estimated 
      to be approximately 0.09. Patients remaining in NYHA class III experienced, on 
      average, a significant improvement (CAMPHOR Utility Index and functioning), which 
      exceeded the MID. The CAMPHOR Utility Index is valid and responsive to change. 
      Patients can experience significant and important improvements even if they do 
      not improve on the basis of traditional outcomes, such as NYHA functional class.
FAU - Meads, D M
AU  - Meads DM
AD  - Galen Research, Enterprise House, Manchester Science Park, Manchester, M15 6SE, 
      UK. david_meads@hotmail.com
FAU - McKenna, S P
AU  - McKenna SP
FAU - Doughty, N
AU  - Doughty N
FAU - Das, C
AU  - Das C
FAU - Gin-Sing, W
AU  - Gin-Sing W
FAU - Langley, J
AU  - Langley J
FAU - Pepke-Zaba, J
AU  - Pepke-Zaba J
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20080903
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Sulfonamides)
RN  - Q326023R30 (Bosentan)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/pharmacology
MH  - Bosentan
MH  - Cost-Benefit Analysis
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*classification/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
MH  - Reproducibility of Results
MH  - *Severity of Illness Index
MH  - Sulfonamides/pharmacology
MH  - United Kingdom
MH  - Walking
EDAT- 2008/09/05 09:00
MHDA- 2009/05/09 09:00
CRDT- 2008/09/05 09:00
PHST- 2008/09/05 09:00 [pubmed]
PHST- 2009/05/09 09:00 [medline]
PHST- 2008/09/05 09:00 [entrez]
AID - 09031936.00069708 [pii]
AID - 10.1183/09031936.00069708 [doi]
PST - ppublish
SO  - Eur Respir J. 2008 Dec;32(6):1513-9. doi: 10.1183/09031936.00069708. Epub 2008 
      Sep 3.